W. Palmer

发表

Development of small molecule inhibitors of BRPF1 and TRIM24 bromodomains.

W. Palmer, 2016, Drug discovery today. Technologies.

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.

Parantu K. Shah, A. Protopopov, B. Vangamudi, 2015, Cancer research.

Determination of Water in Alkylation Sulfuric Acid

W. H. Goff, W. Palmer, R. F. Huhndorff, 1948 .

Observed bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2.

G. Poncet-Montange, Gilbert R. Lee, J. Ladbury, 2015, The Biochemical journal.

Development of indole/indazole-aminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): optimization for JNK potency and physicochemical properties.

A. Kuglstatter, Brian R. Wong, J. D. Dal Porto, 2013, Bioorganic & medicinal chemistry letters.

Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.

C. Rudin, Jason P. Burke, C. Bristow, 2020, Journal of medicinal chemistry.

Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation.

R. DePinho, M. Warmoes, F. Mseeh, 2019, Cell reports.

Palladium-catalyzed reactions of Di-tert-butylsiliranes with electron-deficient alkynes and investigations of the catalytic cycle

W. Palmer, K. Woerpel, K. A. Woerpel, 2001 .

Stereospecific Palladium-Catalyzed Reactions of Siliranes with Alkynes

W. Palmer, K. Woerpel, 1997 .

On the utility of α-heteroatom substituted orthoesters in the Johnson Claisen rearrangement☆

W. Palmer, D. B. Smith, D. Morgans, 1994 .

Synthesis of Silirenes by Palladium-Catalyzed Transfer of Silylene from Siliranes to Alkynes

W. Palmer, K. Woerpel, 1997 .

Discovery of novel PI3-kinase δ specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition.

P. Savy, Steve Price, A. Nadin, 2012, Journal of medicinal chemistry.

Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discovery

B. Vangamudi, M. Kost-Alimova, M. Barton, 2015, Epigenetics & Chromatin.

Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.

Johannes C. Hermann, C. Lukacs, A. Kuglstatter, 2013, Bioorganic & medicinal chemistry letters.

Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor.

G. Poncet-Montange, G. Subramanian, M. Kost-Alimova, 2016, Journal of medicinal chemistry.

N-arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective alpha 1-adrenoceptor antagonists.

A. Ford, T. Williams, M. S. Kava, 1997, Journal of medicinal chemistry.

Joint Meeting on Medicinal Chemistry in Vienna

Peter Mohr, Rainer E. Martin, Wylie Solang Palmer, 2005 .

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.

Parantu K. Shah, A. Protopopov, B. Vangamudi, 2015, Cancer research.

Development of indole/indazole-aminopyrimidines as inhibitors of c-Jun N-terminal kinase (JNK): optimization for JNK potency and physicochemical properties.

A. Kuglstatter, Brian R. Wong, J. D. Dal Porto, 2013, Bioorganic & medicinal chemistry letters.